The zoonotic SARS-CoV-2 virus that causes COVID-19 continues to spread worldwide, with
devastating consequences. While the medical community has gained insight into the …

Abstract COVID-19, caused by SARS-CoV-2 infection, is mild to moderate in the majority of
previously healthy individuals, but can cause life-threatening disease or persistent …

Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant morbidity and …

Objective There is an urgent need to assess the impact of immunosuppressive therapies on
the immunogenicity and efficacy of SARS-CoV-2 vaccination. Methods Serological and T …

To successfully protect against pathogen infection, a vaccine must elicit efficient adaptive
immunity, including B and T cell responses. While B cell responses are key, as they can …

Background As of November 2020, severe acute respiratory syndrome coronavirus 2 has
resulted in 55 million infections worldwide and more than 1.3 million deaths from …

Background In mid-December 2020, Israel started a nationwide mass vaccination campaign
against coronavirus disease 2019 (COVID-19). In the first few weeks, medical personnel …

Background There is uncertainty about the impact of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection in individuals with rare inborn errors of immunity (IEI) …

SARS-CoV-2 is a new beta coronavirus, similar to SARS-CoV-1, that emerged at the end of
2019 in the Hubei province of China. It is responsible for coronavirus disease 2019 (COVID …

Adaptive immune responses play critical roles in viral clearance and protection against re‐
infection, and SARS‐CoV‐2 is no exception. What is exceptional is the rapid …